IRulya Therapeutics Inc.

IRLA Nasdaq SEC CIK 1662774
Follow IRulya Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$27.7M −106.4% vs same quarter last year
EPS, diluted −$2.31
Operating cash flow −$9.8M +0.9% vs same quarter last year
Operating income −$13.1M +2.1% vs same quarter last year
Net income by quarter
−$12.5M
−$15M
−$16M
−$13.4M
−$39.5M
$35.9M
−$75.5M
−$27.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$100M−$75M−$50M−$25M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$84M
FY24−$56.8M
FY23−$31.4M
FY22−$51.7M
FY21−$89.9M
FY20−$76.8M
FY19−$37M
FY18−$12.5M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$41.8M
FY24−$32.2M
FY23−$18.5M
FY22−$44.2M
FY21−$63.1M
FY20−$50.9M
FY19−$33.3M
FY18−$11.9M
FY17-